Browse News
Filter News
Found 18 articles
-
Downstream Processing Market Size to Surpass USD 94.9 Bn by 2030
10/17/2022
According to the global Downstream Processing market size is expected to surpass around USD 94.9 billion by 2030 from valued at USD 31.4 billion in 2021 and growing at a CAGR of 5.2% from 2022 to 2030.
-
Read about TFF Pharmaceuticals and Augmenta Bioworks' dry powder COVID-19 antibody formula, the world's first gene editing clinical trial for PKU, Bayer's COVID-19 vaccine and other key developments in life sciences research.
-
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
-
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
8/16/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced financial results for the second quarter and first half of 2021 and provided business update.
-
The new findings likely throw a wrench in the company's plans to deliver millions of much-needed vaccine doses to the European Union soon.
-
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
6/16/2021
CureVac N.V. (NASDAQ:CVAC), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac's first-generation COVID-19 vaccine candidate, CVnCoV
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
5/26/2021
First-Generation COVID-19 vaccine program, CVnCoV Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities Phase 2a trial in Peru and Panama assessing third booster vaccination at one and six month post second dose CureVac participating in broad UK trial evaluating different COVID-19 vaccines as potential boosters at least three months following full primary vaccination
-
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
4/15/2021
- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission
-
CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
3/23/2021
First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variant CVnCoV induces robust antibody titers with virus variant neutralizing capacity in immunized animals
-
CureVac Expands CVnCoV Covid-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a
3/22/2021
Impact of new SARS-CoV-2 variants supports specification of select strains for anticipated case-driven interim analysis in pivotal Phase 2b/3 study Progress in Phase 2a trial in older adults in Peru and Panama enables addition of secondary vaccine efficacy endpoint CureVac reaffirms intention to apply for formal market authorization in Q2 2021
-
Distribution and administration of the Johnson & Johnson vaccine began this week. There is also additional COVID-19 news. Here’s a look.
-
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV
3/4/2021
Novartis plans to start manufacturing of the mRNA and bulk drug product of CureVac COVID-19 vaccine candidate, CVnCoV, in Q2 2021
-
CureVac and UK Government to Collaborate on Development of Vaccines Against SARS-CoV-2 Variants
2/5/2021
- Collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories - Objective is to mitigate the effects of the current pandemic and to help manage future outbreaks by forming a rapid response unit leveraging the unique strengths of CureVacs mRNA platform
-
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
-
GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines
2/3/2021
Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval
-
Here’s a run-down of some of the most recent collaboration announcements this week.
-
CureVac : CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV
1/7/2021
Bayer has signed a collaboration and services agreement with CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid.